Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 301

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 301
---
 exercise of stock options 
     422  
     - 
  
    Net cash provided by (used in) financing activities 
     18,211  
     (4,225)

    Impact on cash from foreign currency translation 
     224  
     (100)

    NET DECREASE IN CASH 
     (14,926) 
     (16,305)
  
    CASH AT BEGINNING OF YEAR 
     35,848  
     52,153 
  
    CASH AT END OF YEAR 
    $20,922  
    $35,848 

    SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: 

    Cash paid for income taxes 
    $-  
    $- 
  
    Cash paid for interest expense 
    $1,690  
    $1,778 

See accompanying notes to these consolidated financial
statements.

F-6

INMUNE BIO INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND BASIS
OF PRESENTATION

Organization and Business Overview

INmune Bio Inc. (the “Company” or
“INmune Bio”) was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical
company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning
normally and contributing to the patient’s disease. INmune Bio has three product platforms. The DN-TNF product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of
many diseases. DN-TNF is currently being developed for Alzheimer’s and treatment resistant depression (“XPro”) and cancer
(“INB03”) and an out-licensing strategy. The CORDStrom product platform is a pooled, human umbilical cord mesenchymal stem
cell product currently being developed to treat recessive dystrophic epidermolysis bullosa (“RDEB”). The Natural Killer Cell
Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation.

Basis of Presentation and Principles of